MAJI (Exousia Pro) LT-Debt-to-Total-Asset: 0.00 (As of Jan. 2021)


What is Exousia Pro LT-Debt-to-Total-Asset?

Exousia Pro MAJI -1.92% LT-Debt-to-Total-Asset is 0.00 as of Jan. 2021.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Exousia Pro's long-term debt to total assests ratio for the quarter that ended in Jan. 2021 was 0.00.

Exousia Pro's long-term debt to total assets ratio stayed the same from Jan. 2020 (0.00) to Jan. 2021 (0.00).

Exousia Pro  (OTCPK:MAJI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Exousia Pro LT-Debt-to-Total-Asset Related Terms

Exousia Pro LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Exousia Pro's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro LT-Debt-to-Total-Asset Chart

Exousia Pro Annual Data
Trend Apr11 Apr12 Apr18 Apr19
LT-Debt-to-Total-Asset
0.00 0.00 0.00 0.00

Exousia Pro Quarterly Data
Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Exousia Pro LT-Debt-to-Total-Asset Calculation

Exousia Pro's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2019 is calculated as

LT Debt to Total Assets (A: Apr. 2019 )=Long-Term Debt & Capital Lease Obligation (A: Apr. 2019 )/Total Assets (A: Apr. 2019 )
=0/0
=

Exousia Pro's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2021 is calculated as

LT Debt to Total Assets (Q: Jan. 2021 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2021 )/Total Assets (Q: Jan. 2021 )
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Exousia Pro (MAJI) has a LT-Debt-to-Total-Asset of 0.00 as of Jan. 2021. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's LT-Debt-to-Total-Asset too high?
Exousia Pro's current LT-Debt-to-Total-Asset is 0.00.
How does Exousia Pro's LT-Debt-to-Total-Asset compare to HCCH and GRNV?
Exousia Pro's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Exousia Pro and its competitors. Exousia Pro's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Exousia Pro (MAJI), the current LT-Debt-to-Total-Asset is 0.00 as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.